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ABSTRACT
Lysergic acid diethylamide (LSD) is a drug known for its hallucinogenic properties especially at high doses 
and in recent years has been used as a pharmacological model to study the neurological substrate of psycho-
sis, the effect of antipsychotics, and, in recent decades, the possibility of using it as a remedy for some dis-
eases is being studied.
The purpose of this review is to analyze reference reports published in Pubmed, Web of Science, Scopus, 
Google Scholar, articles on preclinical and clinical studies related to LSD, history of use, pharmacokinet-
ic properties, mechanism of action by activating serotonergic, dopaminergic, glutamate receptor systems, 
TAAR₁ receptors, amine receptors and effects on the rewarding brain system, pilot preclinical and clinical 
studies as a therapeutic model for the treatment of depression, anxiety, stress and addictions. We have con-
sidered acute psychotic dose-dependent intoxications and chronic psychosis.
Keywords: LSD, LSD psychosis, LSAD schizophrenia 5-HT2A, LSD acute intoxications, LSD chronic 
intoxications
CLASSIFICATION
Lysergic acid diethylamide (LSD) (C20H25N3O) 
belongs to the class lysergamides or ergoalkaloids. In 
nature, they are found in the fungus Claviceps pur-
purea growing on cereals, mainly rye. LSD is classi-
fied as a drug, psychoactive substance, hallucinogen 
and entheogen/substance for shamanic, mystical and 
religious purposes. As a drug it is on List I (USA); 
Class A (UK); List III (Canada); Annex 1 (Bulgaria). 
In Bulgaria, possession, production and trade in LSD 
are prohibited and prosecuted.
HISTORY
The hallucinogenic properties of the fungus 
Claviceps purpurea have been known for millennia.
The fungus Claviceps purpurea (Fries) grows 
as a parasite on the pistil of some cereals, mainly on 
rye. It is currently collected as a poisonous herb from 
which various alkaloids, nitrogen-containing com-
pounds and ballast substances are isolated. The most 
important are the ergoalkaloids: ergotamine, ergo-
sine, ergozinine, ergocristine, ergocristinine, ergo-
cryptine, ergocryptinine, ergocornine, ergocorni-
nine, ergometrine (ergobazin), ergometrinin (ergo-
metrine). An integral part of these alkaloids is lyser-
gic and isolysergic acid. In folk medicine it is used 
to induce abortion and as gynecological remedy. In 
homeopathy, medicines based on it are used to treat 
blood circulation, with paresthesia and gangrene. In 
medicine they are used as drugs for neuroses and mi-
graines /belergamine and cofergamine/, to stop uter-
ine bleeding, and to strengthen the contraction of the 
uterus /ergot/.
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Claviceps purpurea and its hallucinogenic prop-
erties have been known for centuries. It is believed 
that it was used in ancient Greece in the so-called 
Eleusinian Mysteries /annual celebrations dedicated 
to Demeter and Persephone/. The participants drank 
a drink of barley or rye, fell into a mystical trance 
with bright pictures sent to them by the gods. In the 
Middle Ages, Claviceps purpurea became the cause 
of mass poisoning by falling into the flour. Poisoning 
with it is called ergotism. Symptoms include muscle 
twitching and convulsions, inability to control the 
body, grimacing, confusion, hallucinations, vomit-
ing and diarrhea. They attributed these symptoms to 
the possession of an evil force. In France, the most 
common epidemic outbreaks of ergotism have been 
described, killing thousands of people (about 50 000 
people between 990 and 1130). They called it ergot-
ism and Holy Fire or St. Anthony‘s Fire, because the 
patients were hospitalized in St. Anthony‘s Hospital. 
The Salem Witch believed to have been caused by er-
gotism (1,2,3).
The connection between the consumption of 
flour infected with the fungus was first made by the 
German physician W. Thelius in 1596, and later by 
the French physician Dr. Thuillier in 1670. They be-
lieved that the disease was not infectious, but was due 
to rye containing ergotoxins. The first microbiolo-
gist to observe the fungus now known as C. purpurea 
was Louis Rene Tulasne in 1853, who suggested that 
it produced ergo-alkaloids, not rye itself.
Synthesis of LSD Lysergic Acid Diethylamide
The chemical isolation of ergo-alkaloids took 
place in 1918 and the vasoconstrictor properties of 
ergotamine were proved. In 1938, the Swiss chemist 
Albert Hoffmann (later called the „father of LSD“) 
synthesized lysergic acid diethylamine, or LSD-25, 
from ergot alkaloids in the Sandoz laboratories in 
Switzerland. Hoffmann himself tried the newly syn-
thesized substance and described his first experience 
with LSD as „a journey into the universe of the soul, 
waves of immeasurable happiness flowing through 
the body.“ In his memoirs he writes: „I have experi-
enced the grace of God“ and the feeling that „God is 
in everything“ (4). It was initially thought to be an ef-
fective drug for treating schizophrenia and was used 
in the mentally ill (5).
The Hippie Period of LSD
The mid-20th century, 1960-1980s, were known 
as the “hippie period”. They are largely due to the re-
search of psychiatrists F. Leary /USA/ (6) and Stan-
islav Grof /Czech Republic/ (7). These scientists saw 
in LSD a „magic elixir“ expanding consciousness. 
Adherents of this theory became students, musi-
cians, actors, writers, artists, as well as many hipsters 
and hippies. LSD is associated with groups that dis-
agree with the prevailing cultural and political sit-
uation in the United States and other countries, the 
psychedelic revolution (8), and the hippie movement 
(9). Young people who committed crimes ended up 
in psychiatric clinics and committed suicide. The 
National Survey on Drug Use and Health (NSDUH) 
estimates that more than 22 million (9.1% of the US 
population) have used LSD at least once in their lives 
(8). LSD was recognized as a drug criminalized in 
1965 and banned in the early 1970s, both in the Unit-
ed States and in most countries.
However, lysergic acid diethylamide continued 
to be studied by psychiatrists, therapists, military 
and intelligence agencies in the following decades 
with varying success (10), and in the last decade there 
was a renaissance in the study of this substance to 
understand brain neurotransmitters and function, as 
well as therapeutic means.
Modern Renaissance of Psychedelics as 
Medicines
Scientific interest in serotonergic psychedel-
ics has increased dramatically over the last decade 
due to the ineffectiveness of available drugs and the 
search for alternative approaches, such as transla-
tional psychedelic biomedicine for patients. Pre-
clinical and clinical pilot studies with LSD, psilo-
cybin and mescaline, in combination with psycho-
therapy in volunteers (11, 12, 13), reported good re-
sults in the treatment of mood disorders (14), anxiety 
(11,15,16), depression (12,16,17), post-traumatic stress 
disorder, cancer and fear of impending death (12,17), 
increased emotional empathy in healthy volunteers 
(18), functional neurological disorders (19), inflam-
matory diseases (11), as well as addiction to tobacco, 
alcohol (11,12,14,16,17,20,21) and other drug addic-
tions such as cannabis, stimulants and opiates (13).
The potential antidepressant, anxiolytic and 
anti-addictive effects (17,20,22,24) have been stud-
Scripta Scientifica Pharmaceutica, 2019;6(2):7-21
Medical University of Varna 9
Snezha Zlateva, Petko Marinov, Gabriela Kehayova
ied. The putative mechanisms include acute desta-
bilization of the brain network (serotonin, dopa-
mine and glutamate neurons) resulting in its recov-
ery (11,23,25), as well as changes in the expression of 
genes that contribute to synaptic plasticity, providing 
physiological evidence that these compounds cause 
permanent changes in the brain (15,25-27).
Many of these studies are at an advanced stage, 
but no study to date has shown sufficient efficacy 
(17,19). For example, a study of 536 volunteers with 
chronic alcoholism treated with controlled LSD in-
take showed OR, 1.96; 95% CI, 1.36-2.84; p = 0.0003 
(28). Another study of 343 respondents addicted to 
alcohol, assessed as severely addicted, and using me-
dium and high doses of LSD or psilocybin at home, 
showed that 83% of them, after that, no longer met 
the criteria for severe alcohol dependence and re-
duced drinking (29). A recent online study in the 
United States of 444 cannabis, stimulant and opiate 
addicts found that drug addiction was estimated to be 
79% severe before psychedelic use, and after LSD and 
psilocybe use at home, the severity score dropped to 
28% (13). All participants shared that they approved 
of „psychedelic-related changes in life priorities or 
values such as facilitating reduced alcohol and other 
drug abuse.“ Although these results do not seem con-
vincing, the authors conclude that “naturalistic psy-
chedelic use can lead to the cessation or reduction of 
problem alcohol and drug use” (13,29). Another on-
line study with similar findings surveyed 358 tobac-
co addicts (21). The results showed that after using 
psychedelics at home, 38% quit long-term smoking 
within the next 2 years, and 28% reduced the amount 
of cigarettes, affective withdrawal symptoms such as 
depression and cravings were more tolerable. The 
authors conclude that psychedelics are a promising 
treatment for tobacco dependence through spiritual 
experiences, changed priorities and values, and im-
proved emotional regulation (21).
EXPOSURE WAYS
Mucosal resorption, ingestion, snorting and 
intravenous administration are known. Doses are 
measured in micrograms (μg) and the dose can vary 
between 100 and 500 μg.
The most common way of exposure is oral ad-
ministration, with micrograms of LSD placed on 
blotting paper. The blotting paper (usually decorat-
ed and perforated) is divided into about 1/4 squares, 
called sections, and soaked in a dilution of lysergic 
acid diethylamide. A separate section usually con-
tains between 30-100 µg LSD, and the variations are 
wide depending on the skills of the chemist.
It is also possible to take it in the form of gelatin. 
They are known as „window glass“. Gelatin LSD is 
made by mixing liquid LSD with gelatin and forming 
it into small, thin squares. The benefit of this method 
is that less of the LSD is exposed to the sun and air, 
which breaks down lysergic acid diethylamide. One 
square of gelatin usually contains 50-150 µg of LSD.
Liquid LSD is soluble in water and other sol-
vents, although liquid LSD is usually soluble in eth-
yl alcohol or water. Liquid LSD is used for placement 
on blotting paper to form labels, but can also be used 
for intravenous administration. One drop of a pow-
erful LSD liquid can be 50 times the normal dose, al-
though it is usually diluted to the point where one 
drop equals approximately one dose. This varies 
considerably from batch to batch and is sometimes a 
weak dose, while other times it is a very strong dose. 
It is often stored in small dropper bottles. The use of 
liquid LSD carries the greatest risk of overdose. The 
liquid form can be administered by nasal insuffla-
tion or by intravenous injection.
TOXICOKINETICS (ADME)
Absorption (A): LSD is rapidly absorbed 
through the mucous membranes. The initial clinical 
effects begin after 15-20 minutes.
The maximum plasma concentration is reached 
within 60 minutes after ingestion, and the plasma 
concentration depends on the dose taken, for exam-
ple, at 200 µg it is twice the plasma concentration at 
100 µg (30). In an experiment with healthy volunteers 
(31) who received 200 µg of LSD, the lowest measur-
able plasma concentration was> 0.1 ng/mL within 12 
hours of dosing. The maximum measurable plasma 
concentration is 4.5±1.4 ng/mL, reaching 1.5 (0.5-4) 
hours after administration. The concentrations then 
decrease with a half-life of 3.6±0.9 hours (31).
Distribution (D): Plasma protein binding is 
greater than 80% and the volume of distribution is 
0.3 l kg -1.30.
The most significant amount of LSD penetrates 
the central nervous system, concentrating in the vi-
sual brain areas and the reticular activating sys-
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tem (30,32-35). The effects measured in a controlled 
study started between 21 and 48 minutes after taking 
LSD at doses of 200 µg and 100 µg in the mouth (30).
Metabolism (M): LSD is metabolized to me-
tabolites (nor-LSD and OH-LSD) by deacylation re-
actions (36). The metabolite 2-oxo-3-hydroxy LSD 
/ (OH-LSD) is the major human metabolite, the de-
tection and quantification of which is important for 
clinical and forensic toxicology (37-39).
In vitro controlled studies have shown that liv-
er microsomes are slightly involved in the formation 
of metabolites (<1% metabolites) for 4 hours. Other 
isoforms of CYP 450 show a significant contribution, 
for example, CYP2D6, 2E1 and 3A4 to the formation 
of nor-LSD, and CYP1A2, 2C9, 2E1 and 3A4 signifi-
cantly participate in the formation of OH-LSD (38). 
OH-LSD shows significantly lower affinity and ac-
tivity to serotonergic receptors compared to LSD and 
has no hallucinogenic properties, while nor-LSD has 
hallucinogenic properties similar to LSD. These data 
suggest that genetic polymorphisms and drug inter-
actions could affect the pharmacokinetics and phar-
macodynamics of LSD (38).
The elimination half-life T1/2 is 2 to 5 hours, 
and at a dose of 200 µg it is 8.9 ± 5.9 hours. Minimal 
amounts in the blood can be detected up to 12 hours 
after ingestion (30,31).
A study in 13 patients showed that, when taken 
orally at 160 µg LSD, LSD was detected in the blood 
from 2 to 5 hours (40).
Excretion: Less than 1% is excreted as un-
changed LSD compound and 13% as the OH-LSD 
metabolite. Elimination is linear and ends in the 
order of 12 hours at 100 µg and 24 hours at 200 µg 
(30,31).
Intravenous Administration
When administered intravenously at a dose of 2 
µg/kg, the mean plasma half-life is 175 minutes (30).
TOXICODYNAMICS / MECHANISM 
OF TOXIC ACTION
Threshold Dose
The subjective effects after taking LSD are dose-
dependent (18,30,31).
The threshold dose is 10-20 μg, a low dose is 20-
75 μg, a dose causing the usual effects is 50-150 μg, a 
strong dose is 150-400 μg, and a very strong dose is 
over 400 μg.
The lethal dose is 12 000 μg, which is 30 times 
the „strong“ single dose (18).
The effects at a dose of 100 μg LSD start after 
about 20 to 40 minutes, the average duration of the 
effects is about 8 hours (between 5 and 14 hours). 
Peak effects are observed on average on the third 
hour of intake (between 1.2- 4.6 hours) (30).
The effects at a dose of 200 μg also start after 
about 20 minutes, the average duration of effects is 
about 11 hours (between 6 and 19 hours). Peak effects 
are observed on average in the second hour of intake 
(between 0.8-4.4 hours) (30).
Specific mystical experiences, according to a 
controlled study, show that transcendental experi-
ences do not correlate with plasma LSD concentra-
tions (42).
Individual Sensitivity
Different people have a pronounced individual 
reaction to a single dose of LSD. Some respond poor-
ly, while others have pronounced toxic effects of the 
same dose. The explanation for this is the phenotyp-
ic difference in the sensitivity of serotonin and dopa-
mine receptors (43).
Mechanism of Toxic Action
Numerous studies on LSD psychosis have 
shown that lysergic acid diethylamine affects many 
brain structures,  the so-called pleiotropic action. 
LSD affects brain neurotransmission (via serotonin, 
dopamine, trace amino acids TAAR1 and glutamate 
receptors); changes brain activity; acts on the fron-
tal lobe of a rewarding brain system and activates the 
sympathetic autonomic nervous system.
Serotonin System and LSD
LSD is structurally similar to serotonin. This 
leads to the idea that serotonin is involved in the 
pathogenesis of psychosis, which is now considered 
a well-known fact. LSD acts as a complete or partial 
agonist of the serotonin receptors 5-HT2A, 5-HT1A, 
and 5-HT2C. The hallucinogenic potency of LSD is 
due to binding to the 5HT2A receptor (44-47), while 
binding to 5-HT1A and 5-HT2C receptors has modu-
lating functions (48-51).
Dopamine System and LSD
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Numerous studies in recent years have shown 
that the pathogenesis of psychosis is due not only to 
activated serotonin receptors, but rather to the con-
nection between serotonin and dopamine neurons 
(52,53).
LSD stimulates dopamine D1 and D2 receptors 
(54-58). LSD binds to the D1 and D2 receptors as a 
partial agonist (59) and to the D4 receptor as a full 
agonist (60).
The studies of Bunzow et al. in 2001 (61) on rats 
and subsequent studies (62,63) demonstrated that 
TAAR1 receptors, widespread in the brain and pe-
ripheral nervous system, were involved in the patho-
genesis of psychosis by interaction with the dopa-
minergic system. These receptors are G-coupled 
and are stimulated endogenously by so-called trace 
amines (TAs), a subset of biogenic amines, includ-
ing phenylethylamine (PEA), p-tyramine (pTyr) and 
tryptamine, formerly referred to as false neurotrans-
mitters (61,64-68). Abnormal levels of TAs have been 
linked to a variety of neuropathological disorders, 
including schizophrenia (69-74), major depression 
(74), Parkinson‘s disease (75-78), and bipolar disor-
der (78, 79).
Studies show that these receptors are exoge-
nously stimulated by amphetamines, methamphet-
amines, ecstasy, and LSD. Stimulation of TAAR1 re-
ceptors leads to the production of cAMP and abrupt 
activation of dopaminergic neurons D2 in the ven-
tral tegmental region. D2 receptors in the mesolimbic 
dopamine system mediate not only psychotic symp-
toms but also the brain‘s reward system, particular-
ly the nucleus accumbens, which is considered the 
brain‘s „pleasure center“ (71,80,81). In recent years, 
TAAR1 receptors have been identified as a new ther-
apeutic target in the treatment of psychotic disorders, 
an important modulator of the dopaminergic, sero-
tonergic systems (64-68), and, potentially, the gluta-
matergic system (64).
LSD and Glutamatergic Receptors
In 1999 and later in 2006, it was demonstrated 
that LSD, despite its partial action through 5-HT2A 
receptors, induced phase over-release of glutamate 
on neurons in the prefrontal cortex (82-84).
LSD and the prefrontal cortex (PFC) are an in-
tegral part of the brain‘s reward system.
The effect of LSD on PFC is through the action 
(activation) of serotonergic, dopaminergic, TAAR1 
and glutamatergic neurons, the terminal ends of 
which end in the prefrontal lobe of the brain (85). 
Most of the psychotic and cognitive effects of LSD 
are on PFC (86).
PFC contains pyramidal glutamatergic neu-
rons, which are modulated by several neurotransmit-
ter systems - gamma aminobutyric acid (GABA) in-
terneurons, dopaminergic, noradrenergic, serotoner-
gic, glutamatergic and cholinergic neurotransmit-
ters. It is now known that any change in these sys-
tems as part of the PFC can lead to a change in be-
havior (87).
LSD interacts with adrenergic receptors and 
stimulates the sympathetic autonomic nervous 
system.
LSD stimulates adrenergic receptors (88). Acti-
vation of the sympathetic system leads to increased 
systolic and diastolic blood pressure, tachycardia, 
hyperthermia, sweating, convulsions, increased 




In vitro data on leukocyte treatment with LSD 
indicate that chromosomal fractures and mitotic 
suppression occur in leukocyte culture. Other stud-
ies show that LSD has mild mutagenic effects (92). In 
vitro cell cultures of human cloned D2 receptors were 
assayed for LSD activity (93,94).
Animals
Numerous animal experiments have been per-
formed with LSD to elucidate the pathophysiology of 
psychosis and schizophrenia caused by LSD (95); the 
chronic effects on the behavior of animals at long ex-
posures (96); acute psychosis due to serotonin medi-
ation (53,80,97-99), dopamine (55-58,61,99,100), glu-
tamate (83,84); activation of TAAR1 receptors (80), as 
well as the efficacy of antipsychotic drugs (55). With 
acute and short-term exposure to large doses of LSD, 
rats develop acute respiratory failure and rabbits 
- hyperthermia.
It is claimed that LSD does not lead to physi-
cal dependence in humans, so controlled studies on 
the long-term effects of LSD have only been studied 
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in animals (33,96-105). Chronic administration of 
LSD at doses of 0.08 and 0.16 µg/kg per day for three 
months in rats caused various persistent abnormal 
behaviors, including hyperactivity, hyperreactivity, 
eliminated preference for sucrose solution, changes 
in PFC neurons (103), and changes in social behavior 
that continued for four months after discontinuation 
of LSD (33,103).
At the molecular level, LSD has been shown to 
alter the expression of proteins and genes involved in 
schizophrenia. In fact, LSD increases mRNA expres-
sion for the NMDA receptor subunit NR2A, growth 
factors Bdnf and Krox20, and GABA-A ion channels 
(Gabrb1). LSD reduces the expression of RNA for the 
dopamine receptor gene Drd2, reduces the two sub-
units in the IV zone of the genes (Cox7a2, Cox8a) of 
cytochrome C oxidase, as well as reduces the expres-
sion of genes (Gstt2, Gstp2) for glutathione glutathi-
one S-transferases (103).
People
LSD effects have been studied in well-con-
trolled studies, usually with fixed single doses, tak-
ing into account various parameters such as phar-
macokinetic and pharmacodynamic parameters de-
scribed above; changes in psyche and brain function. 
Various established tools such as psychic tests, such 
as the Minnesota Multiphasic Personality Inven-
tory (MMPI), the Scale for Changing Altered State 
of Consciousness (5D-ASC), the Mystic Experience 
Questionnaire (MEQ), and magnetic resonance im-
aging (MRI), are most commonly used for assess-
ment, as well as electromagnetic encephalography 
(EME), PET positron emission tomography, EEG 
and other methods. These experiments clearly prove 
that the changes are different depending on the dose 
of LSD, both in terms of psychotic experiences and in 
terms of brain activity (33,42,101-116).
There are no long-term controlled studies with 
healthy individuals to assess changes in their behav-
ior after repeated use of LSD, which is explained by 
the fact that it is a drug that is taken from time to 
time and is not considered addictive.
 A controlled study in 2016 analyzed brain ac-
tivity during the period of dosed use of LSD and in 
the period thereafter by MRI and magnetoencepha-
lography, the researchers measured blood flow, func-
tional connections within and between the brain 
networks and brain waves (33,117). Studies show that 
the acute application of LSD significantly reduces the 
functional connectivity in the visual, sensorimotor 
and auditory networks and the default network. On 
the other hand, they found an increased connection 
between the networks of subcortical (thalamus, stria-
tum) and cortical (precuneus, anterior cingulate cor-
tex) structures (117). The mystical experiences them-
selves, according to researchers, are due to the influ-
ence of LSD on the visual cortex. They report a re-
duction in signaling between the parahypocampus 
and the retrosplenial cortex (RSC), and the magni-
tude of the reduction correlates with the subjective 
assessment of „ego dissolution“ and „altered mean-
ing.“ Both conditions are considered hallmarks of 
psychosis (33).
Genetic Research
Studies with volunteers taking LSD show that 
the risk of developing psychosis is more pronounced 
in people with a genetic predisposition to schizo-
phrenia. Eighteen out of 20 relatives of schizophren-
ics develop psychosis (118,119).
Controlled studies among healthy volunteers 
and psychiatric patients showed that psychotic reac-
tions after taking LSD in the group of healthy indi-
viduals were 0.8/1000 in frequency, lasted 48 hours, 
and were not associated with suicide attempts. Com-
pared with patients with psychiatric diagnoses, the 
incidence of psychosis was 1.8/1000 and suicide at-
tempts - 0.4/1000 (69,120).
CLINICAL COURSE OF ACUTE 
INTOXICATION IN HUMANS
LSD causes distortions of perception in hu-
mans and physiological changes. The effects of the 
experience are called a trip. The intensity of the ef-
fects of LSD lasts from 6 to 12 hours depending on 
the dose, tolerance to the drug, weight and age of the 
person. They consist of a change in the psyche and 
autonomic reactions.
Pseudohallucinations
Changes in the psyche include different visu-
al perceptions, different perceptions of time, touch, 
smell, hearing, as well as different sensations of body 
movement and spatial perception of one‘s own body. 
More often, the person with LSD intoxication iden-
tifies these changes in perceptions as unreal events, 
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realizes their illusory nature, therefore they can be 
considered as pseudohallucinations.
At low doses, the following experiences are de-
scribed: rapid change of emotions (euphoria, happi-
ness, fear, anger, laughter, irritation); enhancing the 
sense of music, change in the sense of time; expe-
riencing a feeling of liberation from the shackles of 
the ego and reality; opening the consciousness to su-
pernatural experiences; merge with other objects or 
people; passage of consciousness through different, 
sometimes shocking dimensions of creation; emer-
gence of memories from the period before birth, ac-
cess to ancestral memory and the collective uncon-
scious; sense of the ability to reprogram neural con-
nections in the brain; sense of nirvana, samadhi (en-
lightenment, quantum awakening) (121).
At medium doses, changes in perception of 
time and space, color hallucinations, merging ob-
jects, ego release may be observed. It is claimed that 
this property of the substance is valuable for psycho-
therapists. In a state of „dissolving the ego“, the inhi-
bitions disappear and it is possible for a large amount 
of unconscious soul contents to be pushed to the 
consciousness.
Mystical Experiences
One of the main effects of LSD is the mystical 
experience and experience of the „transcendence of 
time and space,“ which means that one feels beyond 
the past, present, and future and beyond ordinary 
three-dimensional space, into the realm of eternity 
or infinity.
Especially at high doses, „dissolution, disap-
pearance of the boundaries of consciousness and 
merging of the person with the surrounding world“ 
and other mystical and religious experiences occur 
(123). Proponents of LSD often mention that it takes 
several days to prepare for the „journey“ into the 
world of LSD, careful dosing to get the most out of 
the experience.
Hallucinations
Rare are the cases of real hallucinations in 
which the intoxicated ones perceive the changes as 
completely real. Hallucinations usually last between 
8 and 15 hours. They are called a „bad trip“ if there is 
a stream of threatening hallucinations that one con-
siders real and over which there is no control. This 
causes panic and fear, especially of going crazy.
Other possible effects on the central nervous 
system (CNS) include depersonalization, decreased 
ability to think and judge, changes in mood and be-
havior. Patients are usually quiet and withdrawn. 
Cases of aggression and bizarre behavior have been 
described. Acute panic attacks are possible, espe-
cially with unexpected use and less user experience. 
Acute psychotic reactions may also occur. Although 
suicides are rare, the frequency is 0.4/1000 people us-
ing LSD (69,120).
Physiological Effects
Physical examination of people taking LSD re-
veals symptoms characteristic of the so-called sero-
tonin toxin syndrome during the trip: increased sys-
tolic and diastolic blood pressure, tachycardia, hy-
perthermia, sweating, increased muscle tension, 
muscle incoordination and convulsions (89-91). 
There is increased salivation, profuse sweating, nau-
sea, dizziness, lightheadedness, coughing in some 
people, triggering of the sucking reflex or tension in 
the jaws. Unusual bodily sensations such as redden-
ing of the face, chills, influx of physical energy and 
sharpening of the senses (taste, sight, smell, touch) 
are also observed (125).
At high doses, intoxications may occur with se-
vere serotonin syndrome, characterized by hyperre-
flexia, tremor, mydriasis or anisocoria, hyperther-
mia, hypertension, seizures, rhabdomyolysis, and 
coma.
Death
Fatalities have been reported with the use of er-
goalkaloids / poisonous fungus Claviceps purpurea. 
The synthetic variant, LSD, is considered safe at dos-
es between 50 and 200 µg. There have been reports 
of people taking high doses during psychotic experi-
ences under the influence of LSD and suicide, appar-
ently due to threatening hallucinations. Death due to 
cardiovascular collapse and extreme hyperthermia 
(18,91,127,128) has also been reported.
Use by Pregnant Women
LSD can cause chromosomal aberrations and 
an increased risk of congenital anomalies in the fetus 
when used during pregnancy (92).
New Design Compounds
Several LSD derivatives are known, e.g. design-
er drugs based on the molecule of diethylamide of ly-
sergin sykeline 1-acetyl-LSD (ALD-52), 1-propionyl-
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LSD (1PLSD), and 1-butyryl-LSD (1B-LSD). They are 
metabolized to LSD in the body and have similar ef-
fects (129-133).
CHRONIC USE (ABUSE)
LSD may be abused but it is not thought to lead 
to physical dependence. It is very important to real-
ize that addiction and physical dependence are dif-
ferent phenomena with different main substrates of 
the brain.
Addiction (abuse) is a chronically progressive 
disease characterized by compulsive drug use, com-
bined with loss of control and persistent desire for the 
drug. Physical dependence is a result of the develop-
ment of pharmacological tolerance to the drug and 
the onset of withdrawal after abrupt cessation of in-
take (135,136). Most authors accept that LSD is taken 
from time to time for entertainment and is not addic-
tive, but clinical observations show that a large pro-
portion of users take LSD for a long time. The con-
sequences of chronic LSD intake can be unpredict-
able and can have long-term psycho-emotional ef-
fects - both positive and negative. Some people who 
use LSD claim that the effects are very important for 
their lives and this has helped them look at their lives 
from a different angle (13,21,29).
Toxic Effects of LSD in Chronic Use
Due to the presence of individual sensitivity to 
LSD, toxic manifestations of the drug are considered 
to affect only „vulnerable people“ and „at high dos-
es“ and include: /1/ development of so-called „reverse 
changes in the CNS“ in 15 to 77% of users; /2/ perma-
nent hallucinogenic psychosis in about 1%, and /3/ 
trigger of schizophrenia, rarely.
/1/ Sudden reversal of changes in the CNS, 
similar to acute intoxication, e.g. „flashes“
With repeated use of LSD, there is a possibil-
ity of remembering long-forgotten memories or the 
so-called „free trip“.These are short, but sometimes 
very intense flashes of pictures, sounds or emotions - 
pleasant or unpleasant. This psychological phenom-
enon has not yet been fully scientifically explained. 
The experiences are identical to those described in 
the acute use of LSD. Such reverse psychotic chang-
es were observed up to 4 years after the last use of 
LSD. Reverse changes in the CNS occur in 15-77% 
of individuals who use LSD and may completely re-
semble acute intoxication. The return of the mental 
and physiological manifestations of acute intoxica-
tions, after a period of cessation, are provoked main-
ly by various stressful conditions /mental trauma and 
post-traumatic stressful conditions/.
/2/ Hallucinogen persisting perception disor-
der (HPPD)
With repeated abuse of LSD at an average dose 
of 100-200 µg per os, cases of psychosis are also pos-
sible – in approx. 1% of people in the United States 
using LSD (120,124). Psychosis is described as pan-
ic, paranoia and mistrust, metamorphic changes in 
body contours, changes in body image and intense 
visual images with transformative content, the ap-
pearance of suspicious feelings or delusions of great-
ness, confusion, disturbance of thought, hallucina-
tions, lack of will or apathy, catatonic motor behav-
ior, disorganized behavior, regret, depression, lone-
liness, and/or somatic discomfort, all of which can 
be monumental in size (137). Depending on the psy-
chotic content, delusions are classified as persecu-
tory, grandiose, erotic, nihilistic, or somatic. Oth-
er symptoms of LSD-specific psychosis are religious 
delusions and/or pathological hyperreligiousness 
(138-140).
/3/ Unlocking schizophrenia
Psychiatrists initially looked for a substance in 
the brain, similar to LSD, that causes schizophrenia, 
called „schizotoxin.“ It is now accepted that the use 
of LSD does not cause schizophrenia, but substance 
abuse can trigger pre-existing latent schizophrenia. 
The risk is also high in people with parents or rel-
atives with schizophrenia (119,142-145). Schizophre-
nia is diagnosed when the psychotic symptoms last 
for at least six months and include at least one month 
of active psychosis. In LSD-induced schizophrenia, 
some symptoms are assessed as positive, such as hal-
lucinations, delusions, illusions, and disorganized 
thinking, while others are assessed as negative symp-
toms, such as emotional withdrawal and apathetic 
social behavior (146).
CONCLUSION
The interest in LSD is due to the fact that as 
a drug, its recreational use in Bulgaria is growing, 
which raises legal, social and toxicological problems 
that we as experts must answer. On the other hand, 
it is also available as a medicine for addicted patients 
and mental disorders. Therefore, the history of use, 
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its pharmacokinetics and pharmacodynamics, the 
known acute and chronic toxic effects are considered 
in detail. 
For several years in the United States and some 
European countries, the method of „reprogram-
ming“ or so on has been gaining popularity, e.g. 
translational psychedelic biomedicine for patients 
in which serotonergic psychedelics, such as LSD, are 
used as an alternative approach to treating mood dis-
orders, anxiety, depression, tobacco addiction, can-
nabis, stimulants, opiates and alcohol. Theoretically, 
the method consists of acute destabilization of the ce-
rebral network followed by its recovery and improve-
ment of synaptic plasticity. It is therefore important 
to summarize the published results of preclinical and 
clinical pilot studies with LSD and the fact that no 
study to date has shown sufficient efficacy. 
In addition, it is important to clarify all the tox-
ic effects of LSD in acute and chronic use, especially 
by shedding light on the routes of administration, the 
variability of doses in commercially available forms. 
The completeness of this information gives us reason 
to soberly assess the dangers of using the drug LSD 
and carefully follow the evidence from the proposed 
experimental approaches with LSD in the treatment 
of a number of diseases affecting brain neurotrans-
mitters, receptors and synaptic networks.
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